alx-0061
mAbexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01284569)
Timeline
Indications
Mechanism of action
- Interleukin-6 receptor alpha subunitINHIBITOR
IL6R inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- alx-0061
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02437890 | Phase 2 | Jul 1, 2015 | Ablynx |
| NCT02518620 | Phase 2 | Jul 1, 2015 | Ablynx |
| NCT02287922 | Phase 2 | Feb 1, 2015 | Ablynx |
| NCT02309359 | Phase 2 | Jan 1, 2015 | Ablynx |
| NCT02101073 | Phase 1 | Apr 1, 2014 | Ablynx |
| NCT01284569 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Ablynx |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ablynx | For profit | 6 | 6 | 2 | 2011 |
1 organizations
Page 1 / 1